FDA
-
-
-
-
-
-
-
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
-
-
-
-
-
-
-
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
-
-
-
-
-
-
-
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
-
-
-
-
-
-
-
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
-
-
-
-
-
-
-
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
-
-
-
-
-
-
-
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
-
-
-
-
-
-
-
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
-
322,203 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

